Miss Victoria Homer

Miss Victoria Homer

Cancer Research UK Clinical Trials Unit
Senior Biostatistician

Contact details

Address
Cancer Research UK Clinical Trials Unit (CRCTU)
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Victoria is a senior biostatistician at the Cancer Research Clinical Trials Unit (CRCTU) specialising in early phase clinical trials, Bayesian methodology, and trials in (ultra-)rare populations. She is the deputy director of the MRC-NIHR UK Rare Disease Research Platform CAPTIVATE node for trials methodology in rare diseases.

Qualifications

  • MSc Medical Statistics 2019 (University of Leicester)
  • BSc Mathematics (Hons) 2018 (University of Birmingham) 

Biography

Victoria joined the Cancer Research UK Clinical Trials Unit (CRCTU) after completing the MSc Medical Statistics at the University of Leicester and is now a senior statistician within the unit.  She is involved in the design, supervision, analysis and reporting of clinical trials in a variety of oncology and non-oncology clinical areas in both adult and paediatric populations.  She has experience in all phases of trial from first-in-human and dose finding trials to randomised phase III trials of investigational medicinal products, devices, and advanced and cellular therapies. 

Victoria’s work focuses on early phase dose finding and proof of activity clinical trials, Bayesian methodology, and trials in rare diseases. She has a keen interest in improving efficiency in trials, mainly through adaptive designs, novel dose finding methods, and hierarchical and repeated measures analysis. 

Moreover, Victoria is the deputy director of the MRC-NIHR UK Rare Disease Research Platform CAPTIVATE node for trials methodology in rare diseases. This challenge node is aiming to develop innovative clinical trial designs that enable the efficient evaluation of treatments for rare diseases with limited numbers of participants such that the designs and data are acceptable to patients and participants, regulators, and policy makers.

Teaching

MSc Clinical Trials. Module lead for Early Phase Clinical Trials

Other activities

Victoria was recently involved in the Early Development Estimands Nexus of the Oncology Estimand Working Group to develop guidance on the implementation of estimands in phase Ia (dose finding) and Ib (dose confirmatory) trials and sits on external Safety and Data Monitoring Committees for trials at other trials units.

Publications

Recent publications

Article

Srinivasan, V, Homer, V, Barton, D, Clutterbuck-James, A, Jenkins, S, Potter, C, Brock, K, Logan, A, Smith, D, Bruce, L, Nagy, Z & Bach, SP 2024, 'A low molecular weight dextran sulphate, ILB ®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial', PLoS ONE, vol. 19, no. 7, e0291285. https://doi.org/10.1371/journal.pone.0291285

Thaller, M, Homer, V, Abbott, S, Hazlehurst, J, Mollan, SP & Sinclair, AJ 2024, 'Does a Healthy Weight Body Mass Index at Onset of Idiopathic Intracranial Hypertension Change the Outcomes? A United Kingdom Prospective Cohort Study', Neuro-Ophthalmology. https://doi.org/10.1080/01658107.2024.2341775

Hirschfield, G, Arndtz, K, Kirkham, A, Chen, Y-Y, Fox, R, Rowe, A, Douglas-Pugh, J, Thorburn, D, Barnes, E, Aithal, GP, Hull, D, Bhandal, K, Olsen, K, Woodward, P, Lax, S, Newsome, P, Smith, D, Kallio, A, Adams, D, Homer, V & Weston, C 2024, 'Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: open-label, multi-centre, single arm, phase II trial', Hepatology Communications, vol. 8, no. 5, e0426. https://doi.org/10.1097/HC9.0000000000000426

Thaller, M, Homer, V, Mollan, S & Sinclair, A 2023, 'Asymptomatic idiopathic intracranial hypertension: Prevalence and prognosis', Clinical and Experimental Ophthalmology. https://doi.org/10.1111/ceo.14256

Loke, J, Upasani, V, Gaskell, C, Fox, S, Fletcher, R, Thomas, C, Hopkins, L, Kumari, A, Tang, T, Yafai, E, Boucher, R, Homer, V, Toth, A, Chan, YLT, Randall, K, Rider, T, O'nions, J, Drew, V, Pillai, A, Dungarwalla, M, Murray, D, Khan, A, Wandroo, F, Moore, S, Krishnamurthy, P, Huang, YJ, Knapper, S, Byrne, J, Zhao, R, Craddock, C, Parry, H, Moss, P, Stanworth, SJ & Lowe, DM 2023, 'Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes', British Journal of Haematology, vol. 202, no. 3, pp. 498-503. https://doi.org/10.1111/bjh.18894

Englert, S, Mercier, F, Pilling, EA, Homer, V, Habermehl, C, Zimmermann, S & Kan-Dobrosky, N 2023, 'Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development', Pharmaceutical Statistics, vol. 22, no. 5, pp. 921-937. https://doi.org/10.1002/pst.2319

Hyder, YF, Homer, V, Thaller, M, Byrne, M, Tsermoulas, G, Piccus, R, Mollan, SP & Sinclair, AJ 2023, 'Defining the Phenotype and Prognosis of People With Idiopathic Intracranial Hypertension After Cerebrospinal Fluid Diversion Surgery', American Journal of Ophthalmology, vol. 250, pp. 70-81. https://doi.org/10.1016/j.ajo.2023.01.016

Thaller, M, Homer, V, Mollan, SP & Sinclair, AJ 2023, 'Disease Course and Long-term Outcomes in Pregnant Women With Idiopathic Intracranial Hypertension: The IIH Prospective Maternal Health Study', Neurology, vol. 100, no. 15, pp. E1598-E1610. https://doi.org/10.1212/WNL.0000000000206854

Imran, R, Hassouna, T, Sur, G, Casey, A, Homer, V, Barton, D, Brock, K, Altarrah, K & Moiemen, N 2023, 'Efficacy and optimal dose of acetic acid to treat colonised burns woundss: protocol for a pilot randomised controlled trial', BMJ open, vol. 13, no. 9, e058006. https://doi.org/10.1136/bmjopen-2021-058006

Mercier, F, Homer, V, Geng, J, Zhang, H, Englert, S, Kan-Dobrosky, N & Victor, A 2023, 'Estimands in oncology early clinical development: Assessing the impact of intercurrent events on the dose-toxicity relationship', Statistics in Biopharmaceutical Research. https://doi.org/10.1080/19466315.2023.2296648

Thaller, M, Homer, V, Sassani, M, Mollan, SP & Sinclair, AJ 2023, 'Longitudinal prospective cohort study evaluating prognosis in idiopathic intracranial hypertension patients with and without comorbid polycystic ovarian syndrome', Eye (London, England). https://doi.org/10.1038/s41433-023-02569-x

Bailey, S, André, N, Gandola, L, Massimino, M, Wheatley, K, Gates, S, Homer, V, Rutkowski, S & Clifford, S 2022, 'Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial', Cancers, vol. 14, no. 2, 374. https://doi.org/10.3390/cancers14020374

Homer, V, Yap, C, Bond, S, Holmes, J, Stocken, D, Walker, K, Robinson, EJ, Wheeler, G, Brown, S, Hinsley, S, Schipper, M, Weir, CJ, Rantell, K, Prior, T, Yu, L-M, Kirkpatrick, J, Bedding, A, Gamble, C & Gaunt, P 2022, 'Early phase clinical trials extension to guidelines for the content of statistical analysis plans', BMJ, vol. 376, e068177. https://doi.org/10.1136/bmj-2021-068177

Arndtz, K, Chen, YY, Rowe, A, Homer, V, Kirkham, A, Douglas-Pugh, J, Slade, D, Thorburn, D, Barnes, E, Aithal, G, Newsome, P, Smith, D, Adams, D, Weston, C & Hirschfield, G 2022, 'Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial', Efficacy and Mechanism Evaluation, vol. 9, no. 1. https://doi.org/10.3310/ZPNF4670

Comment/debate

Bailey, S, André, N, Gandola, L, Massimino, M, Wheatley, K, Gates, S, Homer, V, Rutkowski, S & Clifford, SC 2024, 'Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers 2022, 14, 374', Cancers, vol. 16, no. 6, 1084. https://doi.org/10.3390/cancers16061084

View all publications in research portal